Your browser is no longer supported. Please, upgrade your browser.
PACB Pacific Biosciences of California, Inc. daily Stock Chart
PACB [NASD]
Pacific Biosciences of California, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own2.10% Shs Outstand154.17M Perf Week13.95%
Market Cap2.59B Forward P/E- EPS next Y-0.44 Insider Trans-20.42% Shs Float151.36M Perf Month83.89%
Income-51.00M PEG- EPS next Q-0.13 Inst Own87.40% Short Float11.48% Perf Quarter265.53%
Sales82.50M P/S31.42 EPS this Y27.30% Inst Trans10.35% Short Ratio4.84 Perf Half Y355.79%
Book/sh0.27 P/B55.37 EPS next Y-1366.70% ROA-27.50% Target Price13.20 Perf Year173.81%
Cash/sh0.69 P/C21.62 EPS next 5Y30.00% ROE-98.30% 52W Range2.20 - 14.53 Perf YTD190.86%
Dividend- P/FCF176.33 EPS past 5Y10.10% ROI-116.60% 52W High2.89% Beta1.24
Dividend %- Quick Ratio1.00 Sales past 5Y8.40% Gross Margin41.10% 52W Low579.55% ATR0.74
Employees404 Current Ratio1.20 Sales Q/Q-30.50% Oper. Margin-60.90% RSI (14)85.43 Volatility5.24% 6.94%
OptionableYes Debt/Eq0.00 EPS Q/Q7.00% Profit Margin-61.80% Rel Volume1.40 Prev Close14.37
ShortableYes LT Debt/Eq0.00 EarningsAug 03 AMC Payout- Avg Volume3.59M Price14.95
Recom2.40 SMA2030.93% SMA5076.88% SMA200202.97% Volume5,014,563 Change4.04%
Oct-02-20Upgrade JP Morgan Neutral → Overweight $15
Sep-09-20Initiated Morgan Stanley Equal-Weight $7
Jun-02-20Resumed Cantor Fitzgerald Overweight $5
Mar-09-20Resumed Cantor Fitzgerald Overweight $5
Oct-15-19Upgrade Piper Jaffray Neutral → Overweight $8
Apr-02-19Downgrade Stephens Overweight → Equal-Weight $4.50 → $8
Oct-19-18Initiated Cowen Outperform
Nov-03-17Downgrade First Analysis Sec Overweight → Equal-Weight $4
Sep-28-17Downgrade CL King Buy → Neutral
Nov-03-16Reiterated Cantor Fitzgerald Buy $18 → $15
Jun-27-16Initiated CL King Buy
Apr-15-16Initiated First Analysis Sec Overweight $11
Feb-04-16Downgrade Piper Jaffray Overweight → Neutral
Jan-04-16Reiterated Cantor Fitzgerald Buy $11 → $18
Oct-23-15Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Initiated Cantor Fitzgerald Buy
Feb-04-15Reiterated Maxim Group Buy $10 → $11
Sep-26-13Reiterated Maxim Group Buy $4 → $8
Jan-14-13Reiterated Maxim Group Buy $3 → $4
Apr-19-11Initiated William Blair Mkt Perform
Oct-19-20 12:30PM  
Oct-15-20 08:00AM  
Oct-08-20 11:30AM  
Oct-06-20 07:44PM  
Oct-05-20 08:00AM  
Oct-02-20 03:37PM  
12:00PM  
Sep-23-20 08:59AM  
Sep-22-20 07:13AM  
Sep-16-20 11:55AM  
Sep-14-20 09:00AM  
Sep-09-20 09:44AM  
Sep-02-20 11:30AM  
Aug-18-20 08:43AM  
Aug-12-20 12:51PM  
Aug-11-20 11:20PM  
04:32PM  
Aug-10-20 01:02PM  
Aug-07-20 08:30AM  
Aug-04-20 08:14AM  
06:40AM  
02:01AM  
Aug-03-20 06:35PM  
04:02PM  
08:05AM  
08:00AM  
Aug-02-20 11:08AM  
Jul-27-20 12:31PM  
Jul-24-20 12:07PM  
Jun-23-20 01:21PM  
Jun-10-20 08:59AM  
Jun-08-20 04:02PM  
Jun-05-20 11:31AM  
May-17-20 06:01PM  
May-08-20 07:57AM  
May-07-20 11:30AM  
May-06-20 04:03PM  
Apr-30-20 10:30AM  
Apr-29-20 12:34PM  
10:39AM  
Apr-27-20 01:09PM  
Apr-24-20 12:30PM  
Apr-21-20 07:22AM  
Apr-20-20 07:00AM  
Apr-08-20 07:30AM  
Mar-18-20 01:52PM  
Mar-07-20 11:31AM  
Mar-05-20 06:00PM  
Feb-25-20 05:40PM  
07:30AM  
Feb-11-20 10:22AM  
Feb-08-20 06:53PM  
Feb-07-20 04:03PM  
07:33AM  
Feb-06-20 06:25PM  
04:02PM  
02:30PM  
Jan-30-20 12:31PM  
Jan-27-20 05:21AM  
Jan-21-20 02:16PM  
Jan-03-20 03:34PM  
02:11AM  
02:05AM  
Jan-02-20 11:58PM  
05:23PM  
04:44PM  
04:05PM  
Dec-30-19 08:31AM  
Dec-18-19 10:05AM  
07:23AM  
Dec-07-19 12:26PM  
11:31AM  
Nov-25-19 08:01AM  
Nov-20-19 08:39AM  
07:14AM  
Nov-07-19 06:55PM  
04:01PM  
Oct-31-19 10:34AM  
Oct-28-19 12:39PM  
Oct-10-19 07:30AM  
Sep-18-19 09:59AM  
Sep-05-19 09:31AM  
Sep-04-19 07:00AM  
Aug-09-19 08:54AM  
Aug-06-19 06:35PM  
Jul-25-19 10:33AM  
Jul-22-19 10:06AM  
Jul-19-19 04:34PM  
12:13PM  
Jul-04-19 06:09PM  
Jun-21-19 10:42AM  
Jun-19-19 09:31PM  
06:41PM  
Jun-18-19 10:09AM  
Jun-13-19 07:30AM  
Jun-02-19 09:30AM  
May-07-19 08:01AM  
May-03-19 04:01PM  
May-02-19 04:17PM  
Apr-24-19 10:33AM  
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hunkapiller MichaelCEO & PresidentAug 25Sale6.44228,6321,472,619934,198Aug 26 05:08 PM
MILLIGAN JOHN FDirectorAug 24Option Exercise3.32110,000365,200110,000Aug 26 07:29 PM
Hunkapiller MichaelCEO & PresidentAug 24Sale6.63259,1641,719,4751,162,830Aug 26 05:08 PM
Hunkapiller MichaelCEO & PresidentAug 21Sale6.57189,8471,246,9151,421,994Aug 24 06:04 PM
Hunkapiller MichaelCEO & PresidentAug 20Sale6.47256,5541,659,8021,611,841Aug 24 06:04 PM
Phillips James MichaelSVP, Research & DevelopmentMar 24Sale3.052,7608,421249,220Mar 24 06:12 PM
Phillips James MichaelSVP, Research & DevelopmentFeb 20Sale4.485,05022,624251,980Feb 24 05:55 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 20Sale4.50166,575749,7541,868,395Feb 24 04:15 PM
BARNES SUSAN KEVP, CFO and PAOFeb 19Sale4.4412,55855,758874,812Feb 25 07:09 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 19Sale4.4976,281342,3492,034,970Feb 20 05:33 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 18Sale4.49525,9952,363,2962,111,251Feb 20 05:33 PM